Mustard gas or sulfur mustard: An old chemical agent as a new terrorist threat

Prehospital and Disaster Medicine

Volumn 24, Issue 1, 2009, Pages 19-29

  Wattana, Monica ^a   Bey, Tareg ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

chemical agents; mustard gas; sulfur mustard; terrorist threat

Indexed keywords

CHEMICAL WARFARE AGENT; MUSTARD GAS;

CHEMICAL WARFARE; DISASTER PLANNING; HISTORY; HUMAN; ORGANIZATION AND MANAGEMENT; REVIEW;

CHEMICAL TERRORISM; CHEMICAL WARFARE AGENTS; DISASTER PLANNING; HISTORY, 20TH CENTURY; HUMANS; MUSTARD GAS;

EID: 84862129800     PISSN: 1049023X     EISSN: 19451938     Source Type: Journal    
DOI: 10.1017/S1049023X0000649X     Document Type: Review

References (64)

1. North Atlantic Treaty Organization (NATO): NATO handbook on the medical aspects of NBC defensive operations AMedP-6(B). Available at http://www.fas.ord/nuke/guide/usa/doctrine/dod/fm8-9/3chl.htm#sl. Accessed 11 December 2008.
2. International Humanitarian Law-Geneva Protocol 1925. Available at http://www.icrc.org/ihl.nsf/intro/280POpenDocument.Assessed 11 December 2008.
3. The Chemical Weapons Convention (CWC). Available at http://www.un.org/ depts/dda/wmd/cwc. Accessed 11 December 2008.
4. Saladi R, Smith E, Persaud A: Mustard: A potential agent of chemical warfare and terrorism. Clin Exp Dermatol 2006;31:1-5.
5. Shohrati M, Peyman M, Peyman A, et al: Cutaneous and ocular late complications of sulfur mustard in Iranian veterans. Cutan OculToxkoi 2007;26:73-81.
6. Szinicz L: History of chemical and biological warfare agents. Toxicology 2005;214:167-181.
7. Bey T, Walter FG: Senfgas, Stickstofflost, Lewisit und Phosgenoxim. Hautschädigende Militärkampfstoffe und deren Bedeutung für die Rettungsdienste, Feuerwehren, Polizei und das Militär. (Mustard gas, nitrogen mustards, lewisite and phosgene oxime. Vesicant-type chemical warfare agents and their significance to the emergency medical services, fire departments, law enforcement agencies and the military [in German with English abstract]. Notfall Rettungsmed 2003;6:327-336.
8. Ghanei M, Harandi A: Long term consequences from exposure to sulfur mustard: A review. J/W7a?/2007:19;451-456.
9. Khateri S, Ghanei M, Keshavarz S, et al: Incidence of lung, eye, and skin lesions as late complications in 34, 000 Iranians with wartime exposure to mustard agent. J Occup Environ Med2003;45:1136-1143.
10. Papirmeister B, Feister AJ, Robinson SL, et al: Medical Defense Against Mustard Gas: Toxic Mechanisms and Pharmacological Implications. Boca Raton: CRC Press, 1991, p 359.
11. Davis K, Aspera G: Exposure to liquid sulfur mustard. Ann Emerg Med 2001;37:653-653.
12. Evison D, Hinsley D, Rice P: Chemical weapons. BMJ 2002;324:332-335.
13. Williams KE: Physical properties of sulfur mustard HD. Available at http://chppm-www.apgea.army.mil/dts/docs/dethhd.pdf. Accessed 29 May 2008
14. Anonymous: Chemical casualties: Vesicants (blister agents). J R Army Med Corps 2002;148:358-370.
15. Sidell FR, Urbanetti JS, Smith WJ, et al: Vesicants. In: Sidell FR, Takafuji ER, Franz DR (eds) Textbook of Military Medicine. Parti, Warfare, Weaponry, and the Casualty. Medical Aspects of Chemical and Biological Warfare. Washington, DC: Office of the Surgeon General, Department of the Army, Walter Reed Army Medical Center, 1997, pp 197-228.
16. Borak J, Sidell F: Agents of chemical warfare: sulfur mustard. Ann Emerg Med 1992;21:303-308.
17. Compton JAG (ed): Blister Agents. In: Military Chemical and Biological Agents Chemical and Toxicological Properties. Caldwell, NJ: Telford Press, 1988, pp 6-86.
18. Peters RA, Sinclair H, Thompson R: An analysis of the inhibition of pyruvate oxidation by arsenicals in relation to the enzyme theory of vesication. BiochemJ 1946;40:516-524.
19. Kehe K, Szinicz L: Medical aspects of sulphur mustard poisoning. Toxicology 2005;214:198-209.
20. Papirmeister B, Gross, CL, Meier, HL, et al: Molecular basis for mustard-induced vesication. Fundam Appl Toxicol 1985;5:sl34-sl49.
21. Korkmaz A, Yaren H, Topal T, Oter S: Molecular targets against mustard toxicity: Implication of cell surface receptors, peroxynitrite production, and PARP activation. Arch Toxicol 2006;80:662-670.
22. Mellor SG, Rice P, Cooper GJ: Vesicant burns. Br J Plast Surg 1991;44:434-437.
23. Watson A, Opresko D, Young R, Hauschild V: Development and application of acute exposure guideline levels (AEGLs) for chemical warfare, nerve, and sulfur mustard agents. J Toxicol Environ Health B Crit Rev 2006;9:163-263.
24. Balali-Mood M, Hefazi M: Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. Basic Clin Pharmacol'Toxicol2006;99:273-282.
25. National Research Council (NRC) Subcommittee on Acute Exposure Guideline Levels, Committee on Toxicology, Board on Enviornmental Studies, Commission on Life Sciences, National Research Council: Standing Operating Procedures for Developing Acute Exposure Guideline Levels for Hazardous Chemicals. Washington, DC: National Academy Press, 2001, pp 1-202.
26. Hartmann HM: Evaluation of risk assessment guideline levels for the chemical warfare agents mustard, GB, and VX. Regul Toxicol Pharmacol2002:35:347- 356.
27. US Army Soldier and Biological Chemical Command: Material Safety Data Sheet. Mustard Gas. Available at http://www.casdeviewuk.com/Frameless/Safe/msds/ ex/MSDS-mustard.htm. Accessed 29 May 2008.
28. Rusch G, Garrett R, Tobin P, etahThz development of acute exposure guideline levels for hazardous substances. Drug Chem Toxicol 2002;25:339-348.
29. Javadi MA, Yazdani S, Sajjadi H, et al: Chronic and delayed-onset mustard gas keratitis: Report of 48 patients and review of literature. Ophthalmology 2005;112:617-625.
30. Vidan A, Luria S, Eisenkraft A, Hourvitz A: Ocular injuries following sulfur mustard exposure: Clinical characteristics and treatment. IMA] 2002;4:577-578.
31. Momeni AZ, Enshaeih S, Meghadadi M, Amindjavaheri M: Skin manifestations of mustard gas: A clinical study of 535 patients exposed to mustard gas. Arch Dermatol 1992;128:775-780.
32. Dacre JC, Goldman M: Toxicology and pharmacology of the chemical warfare agent sulfur mustard. Pharmacol Rev 1996;48:289-326.
33. Ghanei M, Vosoghi AA: An epidemiologic study to screen for chronic myelocytic leukemia in war victims exposed to mustard gas. Environ Health Perspect 2002;110:519-521.
34. Tabarestani M, Farhoudi M, Balali M: Stem Cell and Erythroid Precursors Disorders in Three Patients with Sulfur Mustard Poisoning. In: Proceedings of the First International Medical Congress on Chemical Warfare Agents in Iran, June 1988, Mashhad University of Medical Sciences, Mashhad, Iran. Mashhad, Mashhad University Press, 1988;F10.
35. Tabarestani M, Balali M, Farhoudi M: Hematologic findings of sulfur mustard poisoning in Iranian combatants. Med J Islamic Rep of Iran 1990;3:185-189.
36. Newman-Taylor AJ, Morris AJR: Experience with mustard gas casualties. Lancet 1991;337:242.
37. Willems J: Clinical management of mustard gas casualties. Ann Med Militaris Belgicae 1989;3:sl-s61.
38. Beebe GW: Lung cancer in WWI veterans: Possible relation to mustard gas injury and the 1918 influenza epidemic. J NatlCancer Inst 1960;25:1231-1252.
39. Yamada A: On the late injuries following occupational inhalation of mustard gas with special relationship to carcinoma of the respiratory tract. Acta Pathol Jpn 1963:13;131-155.
40. Hefazi M, Maleki M, Mahamoudi M, et al: Delayed complications of sulfur mustard poisoning in the skin and the immune system of Iranian veterans 16-20 years after exposure. Int J Dermatol 2006;45:1025-1031.
41. Panahi Y, Davoodi S M, Khalili H, et al: Phenol and menthol in the treatment of chronic skin lesions following mustard gas exposure. Singapore Med J 2007;48:392-395.
42. Smith KJ: The prevention and treatment of cutaneous injury secondary to chemical warfare agents. Application of these findings to other dermatologie conditions and wound healing. Dermatol Clin 1999;17:41-60.
43. Rice P, Brown R, Lam D, et al: Dermabrasion-A novel concept in the surgical management of sulphur mustard injuries. Burns 2000;26:34-40.
44. Evison D, Brown RF, Rice P: The treatment of sulphur mustard burns with laser debridement. J Plast Reconstr Aestbet Surg 2006;59:1087-1093.
45. Ghanei M, Shohrati M, Harandi A, et al: Inhaled corticosteroids and long-acting beta2-agonists in treatment of patients with chronic bronchiolitis following exposure to sulfur mustard. Inhal Toxicol 2007;19:889-894.
46. Macintyre AG, Christopher GW, Eltzen E Jr, et al: Weapons of mass destruction events with contaminated casualties. JAMA 2000;283:242-249.
47. Karayilanoglu T, Kenar L, Gulec M: Evaluations over the medical emergency responding to chemical terrorist attack. Mil Med 2003;168:591-594.
48. Kenar L, Karayilanoglu T, Eryilmaz M, et al: Chemical release at the airport and lessons learned from the medical perspective. J Hazard Mater 2007; 144: 396-399.
49. Carmona RH: The science of surge: An all-hazard approach is critical to improving public health preparedness. Acad Emerg Med 2006;13:1097-1097.
50. Kahn CA: Personnel communication, May 2008.
51. Buryakov IA: Express analysis of explosives, chemical warfare agents and drugs with multicapillary column gas chromatography and ion mobility increment spectrometry. J Chromatogr B Analyt Technol Biomet Life Sc 2004;800:75-82.
52. Schwenk M, Kluge S, Jaroni H: Toxicological aspects of preparedness and aftercare for chemical-incidents. Toxicology 2005;214:232-248.
53. Capacio BR, Smith JR, DeLion MT, et al: Monitoring sulfur mustard exposure by gas chromatography-mass spectrometry analysis of thiodiglycol cleaved from blood proteins. ]Anal Toxicol 2004;28:306-310.
54. Makas AL, Troshkov, ML: Field gas chromatography-mass spectrometry for fast analysis. J Chromatogr B Anal Technol Biomed Life Sei 2004;800:55-61.
55. Bowerbank CR, Smith PA, Drown DB, et al: Chemical detection in deployment toxicology using high speed gas chromatography with a solvating mobile phase and time-of-flight mass spectrometry. Drug Chem Toxicol 1999;22:57-71.
56. Muir B, Quick S, Slater BJ, et al: Analysis of chemical warfare agents. II. Use of thiols and statistical experimental design for the trace level determination of vesicant compounds in air samples. J Chromatogr A 2005;1068:315-326.
57. D'Agostino PA, Hancock JR, Chenier CL: Mass spectrometric analysis of chemical warfare agents and their degradation products in soil and synthetic samples. Eur J Mass Spectrom 2003;9:609-701.
58. Garner A, Laurence H, Lee A: Practicality of performing medical procedures in chemical protective ensembles. Emerg Med Australas 2004;16:10S-113.
59. Koenig KL, Boatright CJ, Hancock JA, et al: Health care facilities'"war on terrorism": A deliberate process for recommending personal protective equip-mtnt.Am J Emerg Med 2007;5:185-195.
60. Hurts G: Decontamination. In: Sidell FR, Takafuji ER, Franz DR (eds) Textbook of Military Medicine. TMM Publications Borden Institute, Part I, Warfare, Weaponry, and the Casualty. Medical Aspects of Chemical and Biological Warfare. Washington, DC: Office of the Surgeon General, Department of the Army, Walter Reed Army Medical Center, 1997, pp 351-359.
61. Levitin H, Siegelson H, Dickinson S, et al: Decontamination of mass casualties-Re-evaluating existing dogma. Prehospital Disast Med 2003;18:200-207.
62. Koliek D: Canadian emergency department preparedness for a nuclear, biological or chemical event. CJEM 2003;5:18-26.
63. Taysee L, Daulon S, Delamanche S, et al: Skin decontamination of mustards and organophosphates: Comparative efficiency of RSDL and Fullers earth in domestic swine. Hum Exp Toxicol 2007;26:135-141.
64. Robinson J, Leitenberg M (eds): The Rise in CB Weapons. The Problem of Chemical and Biological Warfare. Volume 1: The Use ofCB Weapons. Stockholm: Alquist and Wiksell Humanities Press, 1971.